About the Campaign
The Campaign for Patient Access was launched by the American College of Cardiology in December 2009 as a national effort to reverse Medicare physician fee schedule cuts that threatened cardiovascular care. The site provided background on the issue, the ACC's legislative and legal response, resources for patients and practices, a newsroom tracking coverage across the country, and ways for supporters to share their stories and support the campaign.
From the Newsroom
Medicare Meltdown: Access to Health Care in "Critical Condition"
A press release warning that cardiology access was in critical condition due to Medicare payment cuts.
Read more
Cardiology Takes Legal Action Against Medicare
The ACC filed suit against HHS Secretary Kathleen Sebelius over the 2010 Physician Fee Schedule.
Read more
ACC Statement on Health Care Reform
The ACC used the State of the Union address to highlight the need to reverse the Medicare cuts.
Read more
Medicare Patients and Physicians Join Petition Drive
Patients and physicians in Washington, DC joined a petition drive calling on Congress for Medicare reform.
Read moreHow Fee Reductions Can Slow New Heart Treatments
Innovative cardiovascular care depends on a long chain of investment. Scientists need grants and laboratory resources, clinical investigators need staff and research sites, and physicians need enough time to identify eligible patients, explain trial participation, and monitor treatment safely. When payment for routine medical services falls, each part of that chain can feel the pressure.
The connection between physician reimbursement and medical research is not always immediate. A reduction in the Medicare physician fee schedule does not automatically cancel a laboratory project or stop a promising therapy from advancing. It can, however, weaken the practices and institutions that make clinical discovery possible, especially in fields such as cardiology where care is complex, time-intensive, and often delivered to older adults with multiple conditions.
The impact of fee reduction on research into new heart treatments therefore deserves attention from patients, physicians, policymakers, and research sponsors. Protecting access to care also helps preserve the clinical infrastructure required to test better drugs, devices, procedures, and approaches to prevention.
Why Physician Payment Matters To Discovery
Cardiovascular research is closely connected to everyday medical practice. A cardiologist who participates in a clinical trial may rely on the same nurses, imaging equipment, electronic records, and scheduling systems used for patient care. The practice may also use its operating margin to support research coordinators, regulatory work, data collection, and staff training.
When Medicare payments decline while labor, technology, malpractice coverage, and administrative expenses continue to rise, practices must make difficult choices. They may reduce appointment availability, postpone equipment upgrades, or limit activities that do not generate reliable revenue. Research can be especially vulnerable because it often requires substantial work before a study produces financial or clinical returns.
Academic medical centers and community practices face different pressures, but both are important. Large hospitals may have dedicated research departments, while community cardiologists often provide access to trials for patients who live far from major institutions. Broad participation makes study findings more representative and gives patients outside urban centers a chance to receive investigational care under careful oversight.
How Fee Reductions Reach Research Budgets
A lower reimbursement rate can affect research through several channels. First, it may reduce the resources available to support personnel. Clinical trials require coordinators to screen records, obtain informed consent, schedule visits, document outcomes, and communicate with sponsors. If a practice cannot cover these costs, it may decline studies even when its physicians and patients are interested.
Second, payment pressure can reduce the time physicians have for scientific work. A trial visit often involves more preparation and documentation than a standard appointment. Physicians must review eligibility criteria, assess risks, interpret test results, and report adverse events. If routine patient care consumes more of the workday, investigators may have less capacity to lead studies or develop research questions.
Third, lower payments can influence which research projects appear feasible. Trials involving complex heart failure, rare diseases, older patients, or multiple chronic conditions may require longer visits and additional monitoring. These studies are medically important but can be harder for financially strained practices to absorb.
| Area affected | Potential effect of lower physician payments | Consequence for heart treatment research |
|---|---|---|
| Staffing | Fewer resources for coordinators and research nurses | Slower enrollment, data collection, and follow-up |
| Physician time | Greater pressure to prioritize billable clinical work | Less capacity to lead studies or assess candidates |
| Practice infrastructure | Delayed investment in imaging, records, and monitoring tools | Fewer sites equipped to conduct complex trials |
| Patient access | Reduced appointments or fewer participating locations | Narrower and less diverse study populations |
| Financial stability | Greater reliance on high-volume services | Less willingness to take on lengthy or uncertain studies |
These effects are cumulative rather than uniform. A well-funded research hospital may withstand a payment change for a period of time, while a small cardiology group may immediately reconsider its participation in a trial. The result can be a research network with fewer sites, longer timelines, and greater geographic inequality.
Clinical Trials Depend On A Stable Care System
New heart treatments cannot be evaluated without patients receiving consistent clinical care. Trials of medications for heart failure, interventions for coronary artery disease, rhythm therapies, and approaches to cholesterol management all depend on reliable follow-up. Investigators need patients to complete visits, undergo testing, report symptoms, and remain engaged over time.
Fee reductions may make this continuity more difficult. If practices cut hours or restrict new patient appointments, potential participants may never be identified. If transportation, scheduling, or care coordination becomes harder, enrolled patients may miss visits. A study can then experience delayed recruitment, higher dropout rates, and less complete evidence.
Representation is another concern. Patients treated in community settings often differ from those seen at major academic centers in age, income, race, geography, and access to specialists. If financial strain pushes research toward a small number of large institutions, trial results may reflect a narrower population. That can make it harder to know whether a treatment will work equally well across the broader Medicare population.
Payment policy also affects the clinical expertise available to research teams. Experienced physicians and nurses understand how a therapy performs in real-world settings and can recognize safety signals that may not appear in controlled laboratory work. Preserving that expertise requires a sustainable practice environment.
The Long-Term Cost Of Delayed Innovation
A reduction in research capacity can create delays that are difficult to see at first. A study may open later, enroll more slowly, or require additional funding to maintain participating sites. Each delay can push back the point at which a treatment is fully evaluated and, if successful, becomes available to patients.
The effects may extend beyond one clinical trial. A practice that stops participating in research may lose trained staff, sponsor relationships, and institutional knowledge. Rebuilding that capacity later can be expensive. Investigators may also move to other fields or institutions, taking experience with them.
This does not mean every physician fee adjustment will produce the same outcome, or that payment increases alone can solve the challenges of cardiovascular research. Drug development also depends on federal funding, private investment, regulatory decisions, patient willingness to participate, and the cost of manufacturing and distribution. Still, reimbursement is part of the ecosystem. A weak clinical foundation can undermine investments made elsewhere.
For patients, the stakes include more than access to a future breakthrough. Research participation can provide an additional pathway to expert evaluation and structured monitoring, although investigational treatments may carry unknown risks and are not guaranteed to help. A healthy research system gives patients more choices while producing evidence that improves care for everyone.
Policy Choices That Can Protect Research Capacity
Policymakers evaluating Medicare physician payment should consider how reimbursement changes affect services that support discovery. Cardiovascular visits involving complex decision-making, longitudinal monitoring, and coordination across specialists require adequate recognition. Payment models that account for time, clinical complexity, and outcomes may help practices maintain both care delivery and research capability.
Research sponsors also have a role. Trial budgets should reflect the actual cost of patient identification, regulatory compliance, data reporting, and follow-up. If site payments fail to cover these responsibilities, participation will be concentrated in organizations with enough reserves to subsidize the work.
Patients and physicians can help make the issue visible by sharing accurate accounts of how payment pressure affects access, staffing, and clinical studies. Personal stories are most useful when paired with clear information about the services at risk and the policy changes that could address them.
Practical priorities include:
- Protect payment for complex cardiovascular evaluation, management, and coordination.
- Include community practices and rural sites in research networks whenever possible.
- Build trial budgets around the full cost of staffing, compliance, and patient follow-up.
- Track whether reimbursement changes reduce enrollment or limit participation by underserved groups.
- Support legislative and administrative policies that preserve access to both specialty care and clinical research.
Keeping New Heart Treatments Within Reach
The future of cardiology depends on a system in which patients can receive care today while physicians and scientists develop better options for tomorrow. Medicare payment decisions influence whether that system has the staff, time, equipment, and stability required to move promising ideas from discovery to tested treatment.
The Campaign for Patient Access has emphasized that protecting physician access is also a way to protect patients’ opportunities to benefit from medical progress. Patients, clinicians, and community leaders can share their experiences, follow legislative and regulatory developments, and urge policymakers to recognize the connection between fair reimbursement and cardiovascular innovation. Speak up for sustainable physician payment and a research system capable of delivering the next generation of heart treatments.
Campaign for Patient Access